SCHEMBL17349760

SCHEMBL17349760

CC(C)(C)C(=O)OCOC(=O)c1cccc2c1OB(O)[C@@H](NC(=O)Cc1cccs1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ MEN1 O00255 5/20 0.36
▸ KMT2A Q03164 5/20 0.36
▸ POLB P06746 4/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ MAPT P10636 3/20 0.35
▸ HSD17B10 Q99714 3/20 0.35
▸ HPGD P15428 3/20 0.35
▸ TSHR P16473 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ CTDSP1 Q9GZU7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17349761 0.91 NPC1 (0.38) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL17349751 0.88 NPC1 (0.48) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL17350001 0.88 TSHR (0.37) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL17349858 0.88 ALDH1A1 (0.36) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL17337154 0.87 PRKCB (0.34) MEN1KMT2AMAPTTSHRMAPK1
SCHEMBL17337157 0.87 PRKCB (0.34) MEN1KMT2AMAPTTSHRMAPK1
SCHEMBL17349945 0.87 PRKCB (0.34) —
SCHEMBL17349747 0.87 MEN1 (0.44) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL17349996 0.87 KMT2A (0.35) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL17349870 0.87 PRKCB (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS SI, ALPI, GAA RAB9A 1272/4885NPC1 2158/4885MEN1 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback